---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-022224"
form_type: "8-K"
ticker: null
cik: "0001501756"
company_name: "Adverum Biotechnologies, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:34:58.178493+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Adverum Q1 net loss $24.8M; cash $193.3M; LUNA Phase 2 interim data to be presented in July

## Summary
- Net loss of $24.8M ($1.50 per share) vs $29.1M in Q1 2023; R&D and G&A expenses decreased.
- Cash, equivalents and short-term investments $193.3M as of March 31, 2024, up from $96.5M year-end; funds into late 2025.
- LUNA Phase 2 interim analysis (26-week landmark) to be presented at ASRS July 17–20, 2024.
- Preliminary LUNA data: 94% and 90% reduction in annualized anti-VEGF injections at 2E11 and 6E10 doses; 85% and 68% injection-free at 26 weeks.
- Ixo-vec generally well tolerated; no serious adverse events, vasculitis, or vascular occlusion reported.

## SEC filing metadata
- accession: 0001628280-24-022224
- form_type: 8-K
- cik: 0001501756
- company_name: Adverum Biotechnologies, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501756/000162828024022224/0001628280-24-022224-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501756/000162828024022224/advm-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-022224
- JSON: https://secwatch.observer/filing/0001628280-24-022224.json
- Plain text: https://secwatch.observer/filing/0001628280-24-022224.txt

## Key facts
- Earnings Releases
  Adverum Biotechnologies, Inc. reported the quarter ended March 31, 2024 results: net income Net Loss was $24.8 million, or $1.50 per basic and diluted share, EPS $1.50 per basic and diluted share.
  - Period: the quarter ended March 31, 2024
  - Net income: Net Loss was $24.8 million, or $1.50 per basic and diluted share
  - EPS: $1.50 per basic and diluted share
  - Result: reported results
  source text: Net Loss was $24.8 million, or $1.50 per basic and diluted share, for the three months ended March 31, 2024, compared to $29.1 million, or $2.90 per basic and diluted share for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501756/000162828024022224/0001628280-24-022224-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.